Is Pharmacyclics the Next Celgene?

Pharmacyclics and Johnson & Johnson have a potential blockbuster in Imbruvica that may put Pharmacyclics on a similar path as Celgene.

Jul 9, 2014 at 2:00PM

Pharmacyclics (NASDAQ:PCYC) has made a big move in the past two years as investors have become increasingly excited by the potential for Imbruvica, a drug being co-developed with Johnson & Johnson (NYSE:JNJ) that won its first FDA approval last November.

Imbruvica has the potential to serve as a major catalyst for Pharmacyclics' future, making the company a major player in cancer and autoimmune drug development similar to Celgene (NASDAQ:CELG).

G

Source: Pharmacyclics.

Following footsteps
Pharmacyclics could do worse than modeling itself after Celgene, which got its start with the approval of Revlimid for myelodysplastic syndromes in 2005.

Revlimid notched label expansions for use in multiple myeloma in 2006 and mantle cell lymphoma in 2013. It become a megablockbuster drug that racked up more than $1.1 billion in sales during the first quarter, up 14% from a year ago.

Celgene has leveraged Revlimid's success to build a successful franchise of other compounds, including Abraxane, Pomalyst, and Otezla.

In 2010, Celgene spent $2.9 billion buying Abraxis to get its hands on Abraxane, a drug used to treat metastatic breast cancer, non-small cell lung cancer, and pancreatic cancer. Sales of Abraxane totaled $185 million in the first quarter, up 50% from last year.

Pomalyst won FDA approval in 2013 for advanced multiple myeloma; its sales have climbed 375% in the past year, to $135 million in the first quarter. And Celgene in March received FDA approval for Otezla, as a treatment for psoriatic arthritis; it may win approval for the drug's use in psoriasis patients later this year.

Celgene has also used Revlimid's cash to fuel a flurry of collaboration deals on next-generation cancer and autoimmune disease therapies, including partnerships with bluebird bio, Agios, Epizyme, and Acetylon.

G

Source: Pharmacyclics

Imbruvica's opportunity may prove similar
Analysts forecast that Imbruvica could generate more than $3 billion in sales annually by 2018.

The drug got its first FDA approval in November 2013 for use in mantle cell lymphoma and won a second approval in February for chronic lymphocytic leukemia.

In the first quarter, those indications delivered $56 million in net product sales that were split equally between Pharmacyclics and Johnson & Johnson. Based on Imbruvica's first-quarter results, Pharmacylics is guiding investors to expect net sales of $80 million during the second quarter and $300 million for the full year.

That's a solid start for Imbruvica, but sales could head significantly higher if ongoing trials for multiple myeloma, diffuse large B-cell lymphoma, and follicular lymphoma result in additional approvals.

It those approvals pan out,  Imbruvica will provide Pharmacyclics with valuable cash that can be used to advance other programs through clinic, including PCI-27483 for the treatment of pancreatic cancer and a highly selective BTK inhibitor that targets arthritis.

G

Source: Pharmacyclics

Fool-worthy final thoughts
Thanks to its partnership deal with Johnson & Johnson, Pharmacyclics has deep pockets and market share-winning marketing might.

Pharmacyclics shares aren't overly cheap based on expected revenue this year, but for long-term investors there may be a solid opportunity -- note that Celgene's market cap is nearly $70 billion, or roughly nine times annual sales. If Imbruvica delivers on analysts' $3 billion projection for annual sales, a similar valuation for Pharmacyclics suggests that its current $7 billion market cap could have room to go higher. 

Leaked: This coming blockbuster may make Pharmacyclics investors jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Celgene and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers